PREPARATION OF VACCINES USING A PHOTOSENSITIZER AND LIGHT

• US 20070059791A1
• Filed: 12/20/2002
• Published: 03/15/2007
• Est. Priority Date: 07/21/1998
• Status: Active Grant

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Navigant Biotechnologies, LLC
• Inventors: Goodrich, Raymond
• Granted Patent: US 7,186,543 B1
• Time in Patent Office: Days
• US Class Current: 435/69.100
• CPC Class Codes: A61K 2039/5152 Tumor cells
• CPC Class Codes: A61K 2039/521 inactivated (killed)
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16063 by chemical treatment
• CPC Class Codes: C12N 2796/00 Viruses not covered by groups C12N2710/00 - C12N2795/00
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but not enough to damage the antigenic characteristics of the infectious particles.

Claims

1. A method of making a vaccine from one or more infectious particles comprising:

inactivating the infectious particles by adding an effective amount of an endogengous isoalloxazine photosensitizer to the one or more infectious particles and exposing the particles to light of a sufficient wavelength to prevent replication of the infectious particles but not substantially destroy the antigenic determinants of the particles; and

suspending the inactivated particles in a suspension solution to create a vaccine.

2. The method of claim 1 wherein the infectious particles are viruses.

5. The method of claim 1 wherein the particles are rendered non-infectious by preventing the replication of the infectious particles.

3-4. -4. (canceled)

6-11. -11. (canceled)

12. A method of making a vaccine containing a live virus comprising the steps of:

adding an effective amount of an endogenous isoalloxazine photosensitizer to the virus and exposing the virus to light of a sufficient wavelength to prevent replication of the live virus but not substantially destroy the antigenic determinants of the virus to create an inactivated live virus; and

suspending the inactivated live virus in a suspension solution to create a vaccine.

13. The method of claim 12 wherein the suspension solution is chosen from the group consisting of:

saline and water.

14. The method of claim 12 wherein the suspension solution comprises an antibiotic and a preservative.

15. The method of claim 12 wherein the suspension solution comprises an adjuvant.

16. A method for inactivating infectious particles without substantially degrading the antigenic characteristics of the particles, comprising the steps of:

exposing the infectious particles to an inactivation fluid containing at least an endogenous isoalloxazine photosensitizer in an amount sufficient to render the particles substantially non-infectious; and

exposing the infectious particles and inactivation fluid to light of a sufficient wavelength and for a sufficient time to render the particles substantially non-infectious but less than that which would result in degradation of the antigenic characteristics of the infectious particles.

17. The step of claim 16 wherein the particles are rendered non-infectious by preventing the replication of the infectious particles.

19. The method of claim 16 wherein the infectious particles are viruses.

22. The method of claim 16 wherein an enhancer is added to the inactivation fluid before the step of exposing the infectious particles and inactivation fluid to light.

18. (canceled)

20-21. -21. (canceled)

23-29. -29. (canceled)